Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for ...

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing ...

The U.S. drugmaker, which has struck multiple partnership deals with gene-editing companies in the last two years, will buy ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a ...